Amgen Q4 profit leaps 30 percent on higher sales (Update)

by Linda A. Johnson
This April 20, 2010, file photo,shows an exterior view of Amgen offices in Fremont, Calif. Biotech drugmaker Amgen Inc. reports quarterly earnings on Tuesday, Jan. 28, 2014.AP Photo/Paul Sakuma, file)

Amgen Inc.'s fourth-quarter profit jumped 30 percent due to higher sales for nearly all its drugs, an acquisition and a tax benefit.

The world's biggest maker of biologic drugs said Tuesday that net income was $1.02 billion, or $1.33 per share, up from $788 million or $1.01 per share a year earlier.

Excluding one-time items, the maker of osteoporosis drug Prolia said earnings amounted to $1.39 billion, or 1.82 per share. Analysts surveyed by FactSet were expecting $1.69 per share.

Revenue totaled $5.01 billion, up 13 percent. Analysts expected $4.81 billion.

In after-hours trading, Amgen shares rose $2.18, or 1.8 percent, to $120.70.

Sales were led by Neulasta and Neupogen for boosting infection-fighting white blood cells, up 8 percent to a combined $1.41 billion. Sales of immune disorder drug Enbrel rose 3 percent to $1.12 billion.

Six other established drugs saw sales increases of 10 percent or more. Those included Prolia, touted in ads by actress Blythe Danner.

Only Aranesp had lower sales, down 4 percent to $180 million due to lower demand.

Sales were boosted by Amgen's $9.7 billion purchase of Onyx Pharmaceuticals Inc. on Oct. 1, part of Amgen's strategy to become a major player in the market for pricey cancer drugs. Onyx's Kyprolis, a treatment for the blood cancer multiple myeloma, posted sales of $71 million.

Also Thursday, Amgen announced that a late-stage patient test of evolocumab, for stubbornly high cholesterol, met the study's two main goals for reducing the absolute level of bad, or LDL, cholesterol and for the average percent reduction. It was tested along with a statin, the widely used cholesterol drugs that include Lipitor and Crestor. Amgen plans to disclose details later at a medical conference and in a medical journal.

The company, based in Thousand Oaks, California, forecast 2014 adjusted earnings per share of $7.90 to $8.20 and revenue of $19.2 billion to $19.6 billion.

For the full year, Amgen reported net income of $5.08 billion, or $6.64 per share, on revenue of $18.68 billion.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Amgen 3Q profit jumps 24 pct. on stronger sales

Oct 22, 2013

Biotech drugmaker Amgen Inc. said Tuesday that its third-quarter profit jumped 24 percent, trouncing analysts' expectations, as sales of more than a half-dozen of its drugs increased by double digits.

IBM posts higher 4Q net income (Update)

Jan 21, 2014

IBM's fourth-quarter net income grew 6 percent, surpassing Wall Street's expectations even though revenue fell. Its shares fell in extended trading after the results came out—and CEO Ginni Rometty said she's recommending ...

Amgen 4Q profit drops 16 pct. on higher spending

Jan 23, 2013

Drugmaker Amgen Inc. on Wednesday posted a 16 percent drop in fourth-quarter profit, as higher costs for production, marketing, research and other items offset higher sales for many of its biologic medicines. The results ...

Recommended for you

What are the chances that your dad isn't your dad?

Apr 16, 2014

How confident are you that the man you call dad is really your biological father? If you believe some of the most commonly-quoted figures, you could be forgiven for not being very confident at all. But how ...

New technology that is revealing the science of chewing

Apr 15, 2014

CSIRO's 3D mastication modelling, demonstrated for the first time in Melbourne today, is starting to provide researchers with new understanding of how to reduce salt, sugar and fat in food products, as well ...

After skin cancer, removable model replaces real ear

Apr 11, 2014

(HealthDay)—During his 10-year struggle with basal cell carcinoma, Henry Fiorentini emerged minus his right ear, and minus the hearing that goes with it. The good news: Today, the 56-year-old IT programmer ...

Italy scraps ban on donor-assisted reproduction

Apr 09, 2014

Italy's Constitutional Court on Wednesday struck down a Catholic Church-backed ban against assisted reproduction with sperm or egg donors that has forced thousands of sterile couples to seek help abroad.

User comments